Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 3/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32677773 | 0.88 | NOD1 (0.51) | DPP4DPP8DPP7NOD1GNPAT | |
| SCHEMBL31326452 | 0.86 | DPP4 (0.40) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL24642680 | 0.86 | DPP4 (0.43) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL24642917 | 0.85 | DPP4 (0.48) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL26528469 | 0.85 | DPP4 (0.45) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL1711313 | 0.83 | FOLH1 (0.54) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL29357446 | 0.83 | FOLH1 (0.54) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL29358689 | 0.83 | FOLH1 (0.54) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL29358709 | 0.83 | FOLH1 (0.54) | DPP4DPP8DPP9DPP7NOD1 | |
| SCHEMBL1711315 | 0.83 | FOLH1 (0.54) | DPP4DPP8DPP9DPP7NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026044039-A2 | ANTI-CD73 ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-02-26 | — | — | WO | claimed |
| US-20260139068-A1 | ANTI-CD73 ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2026-05-21 | — | — | US | disclosed |
| WO-2026044039-A2 | ANTI-CD73 ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-02-26 | — | — | WO | disclosed |
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182569-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-09-06 | — | — | WO | disclosed |
| EP-4257154-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022170971-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州宜联生物医药有限公司 | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139068-A1 | ANTI-CD73 ANTIBODIES, CONJUGATES, AND METHODS OF USE | ENTPD3, ENTPD1, ENTPD2 | DPP4 2383/4885DPP8 1930/4885DPP9 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.